Beta Drugs Limited (NSE:BETA)

Market Cap	14.37B -17.7%
Revenue (ttm)	3.85B +6.2%
Net Income	414.83M -2.2%
EPS	40.92 -2.6%
Shares Out	10.09M
PE Ratio	34.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,674
Open	1,429.50
Previous Close	1,429.50
Day's Range	1,414.00 - 1,459.80
52-Week Range	990.10 - 2,000.00
Beta	-0.45
Analysts	n/a
Price Target	n/a
Earnings Date	May 22, 2026

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 399
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BETA

Financial Performance

In fiscal year 2026, Beta Drugs's revenue was 3.85 billion, an increase of 6.20% compared to the previous year's 3.62 billion. Earnings were 414.83 million, a decrease of -2.21%.